VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Down 38.1% in February

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 1,421,157 shares, a decline of 38.1% from the February 12th total of 2,294,782 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 2,150,188 shares, the days-to-cover ratio is currently 0.7 days. Based on an average daily trading volume, of 2,150,188 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.1% of the shares of the company are short sold.

VolitionRX Trading Down 2.9%

Shares of VNRX stock traded down $0.01 during trading hours on Friday, reaching $0.19. The stock had a trading volume of 1,422,783 shares, compared to its average volume of 1,611,816. The stock’s fifty day simple moving average is $0.25 and its 200 day simple moving average is $0.37. The firm has a market capitalization of $25.81 million, a PE ratio of -0.83 and a beta of 1.34. VolitionRX has a 12 month low of $0.17 and a 12 month high of $0.94.

Institutional Investors Weigh In On VolitionRX

Large investors have recently added to or reduced their stakes in the business. Armistice Capital LLC increased its stake in VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares during the last quarter. Lagoda Investment Management L.P. boosted its position in shares of VolitionRX by 6.7% during the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock valued at $8,476,000 after acquiring an additional 782,000 shares during the last quarter. Citadel Advisors LLC boosted its position in shares of VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of VolitionRX during the fourth quarter worth about $34,000. Finally, Jane Street Group LLC purchased a new position in shares of VolitionRX during the fourth quarter worth about $28,000. Institutional investors own 8.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VNRX. Maxim Group downgraded VolitionRX from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. D. Boral Capital reaffirmed a “buy” rating and set a $3.00 price objective on shares of VolitionRX in a report on Wednesday, January 21st. Finally, HC Wainwright cut their target price on shares of VolitionRX from $2.50 to $1.50 and set a “buy” rating for the company in a research report on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, VolitionRX currently has a consensus rating of “Buy” and an average price target of $2.50.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.